Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant versus tamoxifen in adjuvant breast cancer after aromatase inhibitor intolerance
jRCT2031220056Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Invasive breast cancer-free survival. Started May 2022; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031220056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220056.